Gao F, et al. - Through the databases of PubMed, Embase, and Cochrane Library, researchers conducted a meta-analysis to assess the effectiveness of rituximab (RTX) in neuromyelitis optica (NMO), a severe demyelinating disease that predominantly affects the optic nerve and spinal cord, in terms of safety and tolerance and evaluated the treatment efficacies based on relapse rates and disability. A meta-analysis of 26 studies was carried out with 577 participants. According to results, the relapse-free state was reached by a total of 330 of 528 patients (62.9%). A total of 95 patients out of 577 (16.46%) had adverse reactions. Overall, the investigators suggested that RTX has acceptable tolerance, lowers the frequency of relapse, and improves disability in most NMO patients.